

RESEARCH

Open Access



# The complex interplay between clinical and person-centered diabetes outcomes in the two genders

Maria Chiara Rossi<sup>1\*</sup>, Giuseppe Lucisano<sup>1</sup>, Basilio Pintaudi<sup>2</sup>, Angela Bulotta<sup>3</sup>, Sandro Gentile<sup>4</sup>, Marco Scardapane<sup>1</sup>, Soren Eik Skovlund<sup>5</sup>, Giacomo Vespasiani<sup>6</sup>, and Antonio Nicolucci<sup>1</sup> on behalf of the BENCH-D Study Group

## Abstract

**Background:** New approaches to cope with clinical and psychosocial aspects of type 2 diabetes (T2DM) are needed; gender influences the complex interplay between clinical and non-clinical factors. We used data from the BENCH-D study to assess gender-differences in terms of clinical and person-centered measures in T2DM.

**Methods:** Clinical quality of care indicators relative to control of HbA1c, lipid profile, blood pressure, and BMI were derived from electronic medical records. Ten self-administered validated questionnaires (SF-12 Health Survey; WHO-5 well-being index; Problem Areas in Diabetes (PAID) 5, Health Care Climate Questionnaire, Patients Assessment of Chronic Illness Care, Diabetes Empowerment Scale, Diabetes Self-care Activities, Global Satisfaction for Diabetes Treatment, Barriers to Taking Medications, Perceived Social Support) were adopted as person-centered outcomes indicators.

**Results:** Overall, 26 diabetes clinics enrolled 2,335 people (men: 59.7%; women: 40.3%). Lower percentages of women reached HbA1c levels  $\leq 7.0\%$  (23.2% vs. 27.8%;  $p = 0.03$ ), LDL-cholesterol  $< 100$  mg/dl (48.3 vs. 57.8%;  $p = 0.0005$ ), and BMI  $< 27$  Kg/m<sup>2</sup> (27.2 vs. 31.6%;  $p = 0.04$ ) than men. Women had statistically significant poorer scores for physical functioning, psychological well-being, self-care activities dedicated to physical activities, empowerment, diabetes-related distress, satisfaction with treatment, barriers to medication taking, satisfaction with access to chronic care and healthcare communication, and perceived social support than men; 24.8% of women and 8.8% of men had WHO-5  $\leq 28$  (likely depression) ( $p < 0.0001$ ); 67.7% of women and 55.1% of men had PAID-5  $> 40$  (high levels of diabetes-related distress) ( $p < 0.0001$ ). At multivariate analysis, factors associated with an increased likelihood of having elevated HbA1c levels ( $\geq 8.0\%$ ) were different in men and women, e.g. having PAID-5 levels  $> 40$  was associated with a higher likelihood of HbA1c  $\geq 8.0\%$  in women (OR = 1.15; 95%CI 1.05–1.25) but not in men (OR = 1.00; 95%CI 0.93–1.08).

**Conclusions:** In T2DM, women show poorer clinical and person-centered outcomes indicators than men. Diabetes-related distress plays a role as a correlate of metabolic control in women but not in men. The study provides new information about the interplay between clinical and person-centered indicators in men and women which may guide further improvements in diabetes education and support programs.

**Keywords:** Type 2 diabetes, Gender-disparities, Diabetes-related distress, Psychological wellbeing

\* Correspondence: rossi@coresearch.it

<sup>1</sup>CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy

Full list of author information is available at the end of the article



## Background

The considerable pressure on health care systems to provide high-quality care while controlling costs has led several public and private health care organizations to promote initiatives to measure and improve the quality of care for people with diabetes [1, 2].

In Italy, the Associazione Medici Diabetologi (AMD) scientific society has implemented since 2006 a continuous improvement effort involving a large network of diabetes clinics throughout the country (AMD-Annals) [3]. The periodic dissemination of Annals has been effective in improving several process and intermediate outcome indicators clinical indicators over a few years [4]. The model has also been proven to be cost-effective [5].

Data from AMD-Annals have been recently used to evaluate gender differences in pharmacological and non-pharmacological treatment of diabetes [6]. The analysis was important to demonstrate that gender disparities are less pronounced in Italy than in other countries, but that the likelihood to reach specific clinical outcomes is systematically unfavorable for women as compared to men; in particular, women were 14% more likely than men to have HbA1c levels  $>9.0\%$  in spite of insulin treatment, 42% more likely to have LDL-cholesterol  $\geq 130$  mg/dl in spite of lipid-lowering treatment, and 50% more likely to have BMI  $\geq 30$  Kg/m<sup>2</sup>. These findings suggested that a complex interplay among biological, clinical and behavioral differences can underlie these differences and call for diversifying the care and specializing the support provided to men and women.

In parallel, the increasing recognition of patient-centered care as the best model to ensure a care respectful of, and responsive to patient preferences, needs, and values [7] call for the need to include psychosocial aspects in the quality model of diabetes care, as clearly emphasized by the international Diabetes Attitudes, Wishes, and Needs (DAWN-2) Program [8]. The DAWN-2 study well documented that people with diabetes have major psychosocial issues; in particular, 44.6% (country range 17.2–67.6%) of people with diabetes have diabetes-related distress (i.e. Problem Areas in Diabetes Scale 5 (PAID-5) score  $\geq 40$ ) [9], while 13.8% have likely depression [WHO-5 Well-Being Index (WHO-5) score  $\leq 28$ ] [10] (country range 6.5–24.1%). Furthermore, diabetes had a negative impact on physical health and social relationship; approximately 40% of participants reported that their medication interfered with their ability to live a normal life.

Due to this body of evidence, individualized interventions based on patient needs, concerns, and capabilities have been promoted while taking gender into account.

In the context of the AMD-Annals and the DAWN2 initiatives, the BENCH-D study (Benchmarking Network for Clinical and Humanistic Outcomes in Diabetes) was

launched aiming to test a model of regional benchmarking to monitor and improve not only clinical indicators, but also person-centered outcomes [11]. Besides the AMD clinical indicators for the evaluation of quality of care, the BENCH-D study used validated questionnaires, largely derived from the DAWN2 study, for measuring person-centered dimensions.

The first important step of the BENCH- study was to describe the person-centered indicators in type 2 population and to explore the relationship among different quality of care and quality of life dimensions. As described in two previous papers [12, 13], BENCH-D documented that: high levels of diabetes distress are common among people with type 2 diabetes (T2DM), affecting almost two-thirds of patients; high diabetes distress is associated with worse clinical and psychosocial outcomes; higher empowerment is on the other hand associated with better glycemic control, psychosocial functioning and perceived access to person-centered chronic illness care.

In the present secondary analysis of the BENCH-D data, database has been used to assess gender-differences in T2DM in terms of diabetes-related distress, physical and psychological well-being, empowerment, perceived social support and other measures of satisfaction with treatment and care. We wanted to test the hypothesis that systematic differences exist in the two genders in the interplay between clinical and person-centered indicators, especially on the likelihood on poor metabolic control (i.e. HbA1c  $\geq 8.0\%$ ). A deeper comprehension of these differences may inform individualized, gender-specific educational approaches.

## Methods

A detailed description of the BENCH-D study protocol and of the questionnaires utilized as person-centered indicators was published elsewhere [11]. Briefly, a random sample of patients with T2DM stratified by diabetes treatment (oral agents, insulin + oral agents, insulin) was selected by 26 diabetes outpatient clinics in Italy.

Following the AMD-Annals methodology [3–6], clinical data were extracted from electronic databases of diabetes clinics, including information on body mass index (BMI), diabetes duration, HbA1c, blood pressure and lipid profile values, glucose-lowering, antihypertensive and lipid-lowering treatments, diabetic complications (i.e. retinopathy, diabetic nephropathy, foot complications, and previous cardiovascular and cerebrovascular events). AMD-Annals intermediate outcome measures were evaluated on the BENCH-D sample; these indicators include the proportion of patients with satisfactory values as well as the percentage of those with unacceptably high values. Outcomes were considered satisfactory if HbA1c levels were  $\leq 7.0\%$  ( $\leq 53$  mmol/mol), blood

pressure values were  $\leq 130/80$  mmHg, LDL cholesterol (LDL-c) levels were  $< 100$  mg/dl, and BMI was  $< 27$  Kg/m<sup>2</sup>. Unsatisfactory outcomes include HbA1c levels  $> 8.0\%$ , blood pressure values  $\geq 140/90$  mmHg, LDL levels  $\geq 130$  mg/dl, and BMI  $\geq 30$  Kg/m<sup>2</sup> [6].

Information on socio-demographic characteristics, quality of life, satisfaction, and self-care behaviors and attitudes was collected using an ad hoc self-administered questionnaire including ten validated instruments which are described in Table 1 [9, 10, 14–32]. The scores of these instruments represented the person-centered outcomes. In line with the methodology applied in the DAWN2 study [8], the instruments were

chosen to evaluate the impact of diabetes and its management on physical and psychological well-being and satisfaction. In addition, perceived barriers, diabetes distress, and social support were included as mediators of the relationship between self-care activities, quality of life, and diabetes outcomes. All the instruments were validated and showed satisfactory psychometric properties [9].

All the scores (i.e. person-centered indicators) ranged between 0 and 100, with higher values indicating higher levels of the dimension investigated. The only exception is the SDSCA6 scale [27] that provides a single score for each item, ranging from 0 to 7 to indicate the average

**Table 1** Questionnaires used and validated in the BENCH-D study

Questionnaire	Abbreviation	Domain	Brief description	No. of items	Scoring	References
SF-12 Health Survey - physical component	SF-12 PCS	Physical functioning	SF-12 is a widely used generic health status measure. It includes 12 items which can be aggregated into two summary measures: the Physical (PCS) and Mental (MCS) Component Summary scores. Both scores range from 0 (worst possible health state) to 100 (best possible health state); they are normalized to a general population mean of 50 and an SD of 10.	6	0-100	[14]
WHO-5 well-being index	WHO-5	Psychological well-being	WHO-5 assesses the psychological well-being, a core component of overall quality of life. It is also a valid and reliable risk assessment measure for mild, moderate and severe depression. A score $< 50$ indicates poor psychological well-being, a score $\leq 28$ indicates probable depression.	5	0-100	[10, 15]
Problem Areas in Diabetes	PAID-5	Diabetes distress	PAID-5 evaluates diabetes related emotional distress, i.e. specific worries and negative emotions related to diabetes. A score $> 40$ indicates high diabetes-related distress.	5	0-100	[9, 16–20]
Health Care Climate Questionnaire - Short Form	HCC-SF	Person centered communication	HCC-SF evaluates the extent to which clinicians tend to favor the autonomy of the patient or, instead, tend to assume a paternalistic attitude towards the patient. Higher scores correspond to a higher perception by the patient of autonomy support.	6	0-100	[21, 22]
Patients Assessment of Chronic Illness Care - Short Form	PACIC-SF	Quality of chronic illness care and patient support	PACIC provides an assessment of patient perceived access to support from the health care team according to a chronic care health delivery model. The higher the score the more favorable the patient experience.	11	0-100	[23, 24]
Diabetes Empowerment Scale - Short Form	DES-SF	Diabetes Psychosocial Self-Efficacy	DES-SF assesses the patient's confidence in taking an active role in own management of the condition. The higher the score the higher the patient empowerment	8	0-100	[25, 26]
Diabetes Self-care Activities	SDSCA-6	Self-care activities	SDSCA-6 assesses self-reported health behaviors related to diet, physical activity, self-monitoring of blood glucose, foot care and medication taking. Each item is reported individually.	6	0-7	[27]
Global Satisfaction for Diabetes Treatment	GSDT	Satisfaction with treatment regimen	GSDT assesses overall satisfaction with the medical diabetes treatment, here under the perceived impact of medication on daily life and psychological well being, The higher the score the higher the treatment satisfaction .	7	0-100	[28]
Barriers to Taking Medications	BM	Barriers to taking medication	BM assesses what concrete barriers patients feel they face in daily life to taking their medication as scheduled. The higher the score the higher the perceived barriers.	10	0-100	[29–32]
Perceived social support	PSS	Patient perceived support	PSS assesses satisfaction with social support from various sources for managing diabetes (healthcare system, community, family, peers...). The higher the score the higher the perceived support.	5	0-100	[29–32]

number of days in the previous week respondent had performed each self-care activity. Two dichotomous person-centered indicators were also utilized: percentage of people with WHO-5  $\leq 28$  indicating likely depression [10, 15], and percentage of people with PAID-5  $> 40$  indicating high diabetes-related distress [9, 16–20].

All the clinical and person-centered data collected in the study have been anonymized and centrally analyzed. Local ethics committees of all participating centers approved the protocol.

### Statistical analysis

No formal sample size estimation was performed. Each center was required to enroll up to 100 patients.

Differences in socio-demographic characteristics, clinical outcomes and in mean quality of life/satisfaction scores according to gender were evaluated and compared using the chi-square tests for categorical variables and the Mann-Whitney test for continuous variables. Data were expressed as mean and standard deviation or frequency. A  $p$ -value  $< 0.05$  was considered statistically significant.

Mean scores of questionnaires were also adjusted for age, diabetes duration, BMI, presence of diabetes complications, glucose-lowering treatment class, school education, and living status. Data were expressed as mean and standard error.

Fully adjusted multivariate logistic models, separated for men and women, were applied to identify socio-demographic, clinical and person-centered factors associated with the achievement of HbA1c levels  $\geq 8.0\%$  in the two genders. Results are expressed as Odds Ratios (ORs) with their 95% confidence intervals (95%CI). All statistical analyses were performed using SAS 9.4 (The SAS Institute, Cary, NC, USA),

### Results

Between January 2010 and July 2011, 26 diabetes clinics enrolled 2,390 people with T2DM; information on gender was available for 2,335 (97.7%); men were 1,393 (59.7%) and women were 942 (40.3%). Population characteristics by gender are reported in Table 2: compared to men, women were slightly older, had a lower level of school education, and were more likely to live alone. Women were less frequently smokers than men. From a clinical point of view, despite a longer diabetes duration and a higher likelihood to be treated with insulin, women showed a lower prevalence of known diabetes complications than men. Higher levels of HbA1c, total and LDL-cholesterol and BMI were found in women and AMD-Annals intermediate outcome indicators were systematically less satisfactory in women than in men, with lower

percentages of women reaching favorable therapeutic goals for HbA1c, lipid profile and BMI than men, and parallel higher percentages of women with unacceptably high levels of the same parameters (Fig. 1).

Between-gender differences in person-centered indicators are shown in Table 3. Women had statistically significant poorer scores for physical functioning, psychological well-being, self-care activities dedicated to physical activities, empowerment, diabetes-related distress, satisfaction with treatment, barriers to medication taking, satisfaction with access to chronic care and healthcare communication, and perceived social support than men. On the other hand, women showed higher adherence than men to self-care activities dedicated to self-monitoring of blood glucose and foot monitoring. The comparison of scores between genders after adjusting for clinical and socio-demographic characteristics showed that the difference in empowerment scores was no longer significant, while all the other differences remain consistent with the crude scores (Table 3). One in four women and one in ten men showed likely depression (WHO-5  $\leq 28$ ), while two in three women and one in two men showed high diabetes-related distress (PAID-5) (Fig. 2).

In a multivariate analysis, factors associated with an increased likelihood of having elevated HbA1c levels ( $\geq 8.0\%$ ) were different in men and women (Table 4). In particular:

- Both in men and in women, insulin treatment alone or in association with OHAs increased the likelihood of having HbA1c  $\geq 8.0\%$  from 13 to 33% vs. OHAs only;
- In men but not in women, the likelihood of having HbA1c  $\geq 8.0\%$  decreased as age increased ( $-3\%$  for each additional 5 years) and was associated with the level of school education;
- In women but not in men, high levels of diabetes related distress were associated with a higher likelihood of poor metabolic control.

### Discussion


Data from the BENCH-D study provide new insights into the quality of care and quality of life as perceived by men and women with T2DM. Health related quality of life represents not only a key outcome of any person-centered chronic care model, but also an important mediator for adherence to treatment and the achievement of therapeutic goals.

Our data show, in line with the results of AMD-Annals [6], that women with T2DM have poorer intermediate outcome indicators than men, i.e. higher levels of HbA1c and poorer control of key cardiovascular risk factors such as BMI and LDL-cholesterol. Data also

**Table 2** Socio-demographic and clinical characteristics according to gender

		Men	Women	p <sup>a</sup>
N		1393	942	
%		59.7	40.3	
Socio-demographic characteristics				
Mean age (years)		64.4 (10.0)	66.1 (10.4)	<0.0001
Age in classes (%)	<55	17.5	14.8	<0.0001
	55–65	33.3	27.6	
	65–75	35.3	37.8	
	> = 75	13.9	19.7	
School education (%)	Primary school	30.3	53.4	<0.0001
	Middle school	32.7	22.9	
	High school	28.4	19.8	
	University	8.6	3.9	
Working status (%)	Employed	30.5	12.0	0.77
	Housewife	0.7	34.8	
	Retired	65.8	51.9	
	Unemployed/student	3.1	1.3	
Living status (%)	Alone	8.7	16.7	<0.0001
	Spouse/sons	84.8	79.8	
	Other	6.5	3.4	
Clinical characteristics				
Smokers	No	33.5	73.2	<0.0001
	Yes	20.2	11.4	
	Ex	46.3	15.5	
BMI (Kg/m <sup>2</sup> )		29.7 (5.9)	31.0 (6.1)	<0.0001
Diabetes duration (years)		13.4 (15.1)	15.5 (15.6)	0.006
Mean HbA1c (%)		7.6 (1.5)	7.8 (1.5)	0.002
Total cholesterol (mg/dl)		170.9 (38.1)	187.3 (40.4)	<0.0001
LDL cholesterol (mg/dl)		96.9 (31.1)	106.7 (34.4)	<0.0001
HDL cholesterol (mg/dl)		46.7 (13.9)	54.1 (14.2)	<0.0001
Triglycerides (mg/dl)		142.8 (116.4)	140.0 (100.6)	0.64
Systolic blood pressure (mmHg)		135.1 (15.8)	135.8 (16.8)	0.39
Diastolic blood pressure (mmHg)		78.3 (9.3)	78.2 (8.8)	0.97
Diabetes treatment (%)	Oral agents	52.6	44.9	0.001
	Oral agents + insulin	23.0	27.2	
	Insulin	24.3	27.9	
Lipid-lowering treatment (%)		48.5	47.6	0.65
Antihypertensive treatment (%)		67.6	70.4	0.16
No. of diabetes complications	0	63.7	70.0	0.0001
	1	26.1	23.9	
	> = 2	10.2	6.2	


<sup>a</sup>  $\chi^2$ -square test for categorical variables and the Kruskal-Wallis test for continuous variables



**Table 3** Person-centered indicators in men and women with type 2 diabetes. Crude data are expressed as mean and standard deviation (std); adjusted data are expressed as mean and standard error (se)

Person-centered care indicator	Person-centered indicator	Crude scores			Adjusted scores <sup>a</sup>		
		Men	Women	p-value	Men	Women	p-value
		Mean (std)	Mean (std)		Mean (se)	Mean (se)	
Physical functioning	SF12 – PCS	44.9 (9.1)	40.3 (9.9)	<0.0001	44.0 (0.32)	40.8 (0.37)	<0.0001
Psychological well-being	WHO-5	62.5 (21.1)	49.5 (23.7)	<0.0001	61.2 (0.80)	50.7 (0.96)	<0.0001
Self-care activities	DSCA-Diet	5.0 (1.9)	5.0 (2.0)	0.79	4.9 (0.07)	5.0 (0.09)	0.26
	DSCA-Exe	3.4 (2.6)	2.7 (2.5)	<0.0001	3.1 (0.09)	2.7 (0.11)	0.002
	DSCA-SMBG	3.8 (2.6)	4.3 (2.5)	<0.0001	3.8 (0.09)	4.2 (0.10)	0.004
	DSCA-Feet	3.2 (2.8)	3.8 (2.8)	<0.0001	3.1 (0.10)	3.9 (0.12)	<0.0001
	DSCA-Drugs	6.6 (1.4)	6.6 (1.4)	0.89	6.6 (0.05)	6.6 (0.06)	0.88
Empowerment	DES	80.3 (15.3)	78.4 (16.2)	0.004	78.5 (0.56)	77.8 (0.66)	0.46
Diabetes distress	PAID-5	42.0 (26.9)	51.4 (28.1)	<0.0001	41.8 (1.00)	49.4 (1.19)	<.0001
Satisfaction with treatment	GSDT	80.7 (11.9)	78.8 (12.9)	0.0004	80.8 (0.44)	79.1 (0.53)	0.01
Barriers to medication taking	BM	24.4 (9.1)	26.0 (10.5)	<0.0001	24.1 (0.33)	25.7 (0.39)	0.003
Experience of access to chronic illness care	PACIC	74.8 (15.8)	73.5 (16.5)	0.05	74.3 (0.60)	72.4 (0.71)	0.05
Experience of health care communication	HCCQ	88.8 (14.2)	87.4 (15.4)	0.03	88.4 (0.52)	86.9 (0.62)	0.06
Perceived social support	PSS	81.1 (15.4)	78.2 (15.1)	<0.0001	80.8 (0.52)	77.3 (0.63)	<.0001

<sup>a</sup> adjusted for age, diabetes duration, BMI diabetes complications, glucose-lowering treatment scheme, school education, and living status



**Fig. 2** Between-gender differences in the prevalence of likely depression (WHO-5 <=28) and high diabetes-related distress (PAID-5 >40)

show that, compared to men, women have lower levels of general well-being, diabetes-related quality of life, satisfaction with treatment and care, self-care attitudes dedicated to physical activity, and empowerment. On the other hand, women report a higher level of adherence to SMBG and foot monitoring. It has been documented that SMBG not supported by adequate education to develop skills to modify therapy and behaviors based on the SMBG readings can worsen quality of life [33].

Our data also show that gender differences in the level of empowerment are largely dependent on the differences in the socio-demographic and clinical characteristics, while all the other person-centered indicators remain less satisfactory in women than in men also after adjustment for patient case-mix. This suggests that the lower socioeconomic status of women with T2DM in our sample was associated with autonomy and informed decision-making, as well as problem solving and goal setting (i.e. the areas covered by the DES scale) [34], but not with the general and diabetes-specific dimensions of quality of life and patient satisfaction investigated through all the other questionnaires.

Finally, at multivariate analysis adjusted for all the patient characteristics, in men the likelihood of poor glycemic control (HbA1c  $\geq 8.0\%$ ) was associated with socio-demographic and clinical characteristics, i.e. age, school level, and insulin treatment (to be intended as a proxy of diabetes severity), while in women insulin treatment and diabetes-related distress, but not socio-demographic characteristics played a role.

Patients with higher diabetes-related distress put a greater weight on their disease, which absorbs daily mental and physical energy. Higher diabetes related emotional distress levels are associated with lower patient adherence and empowerment levels [35, 36]. Our

data show that diabetes distress plays a role as a correlate of good metabolic control in women but not in men.

The study suggests that new gender-specific approaches to cope with clinical and psychosocial aspects of diabetes may be needed. The interplay among clinical and non-clinical factors is complex and gender influences the relationship between the different components.

The existence of gender-specific needs has been suggested by a relevant body of literature and healthcare systems are increasingly challenged to consider the different health issues of women and men in terms of prevention, clinical signs, therapeutic approach, prognosis, psychological and social impact [37].

From a mere clinical point of view, a gender-based approach in the management of T2DM must consider the different CVD profile of men and women. In fact, although the overall CVD risk is higher in T2DM men, the relative risk of coronary heart disease (CHD) is higher in T2DM women when compared to people without diabetes, with the loss of the typical oestrogen protection in the premenopausal state [38]. Diabetes is a powerful cardiovascular risk factor for both genders, but the relative risk of coronary heart disease deriving from having T2DM is higher in women than in men [39, 40]. Multiple factors are responsible for these differences, including gender-differences in metabolic control, cardiovascular risk, and treatments [41, 42], especially disparities in the routine management of LDL-C levels [43].

From a psychosocial point of view, many differences exist between men and women in beliefs, attitudes, fears and concerns about diabetes and its management [44]. In particular, women report significantly more depressive symptoms than men [45], female sex is a predictor of poor psychological outcomes [46], and depressive

**Table 4** Factors associated with increased likelihood of poor metabolic control (HbA1c > =8.0%)

Covariates <sup>a</sup>	Categories	Men		Women	
		OR	95%CI	OR	95%CI
AGE by 5 years		<b>0.97</b>	<b>0.95–0.99</b>	0.98	0.96–1.00
School education	High school or university	<b>0.87</b>	<b>0.80–0.95</b>	0.92	0.82–1.03
	Middle school	0.95	0.87–1.03	0.94	0.84–1.05
	Primary school	1.00	-	1.00	-
Living status	Spouse / sons	1.00	-	1.00	-
	Alone	0.89	0.77–1.03	1.08	0.97–1.22
	Other	1.01	0.88–1.15	1.14	0.93–1.39
Smoker	Ex	0.99	0.92–1.07	1.05	0.94–1.17
	Yes	0.97	0.89–1.07	1.03	0.89–1.20
	No	1.00	-	1.00	-
BMI	0–27.0	<b>0.91</b>	<b>0.84–0.99</b>	0.93	0.84–1.03
	27.1–30.0	<b>0.89</b>	<b>0.82–0.97</b>	0.91	0.82–1.01
	>30.0	<b>1.00</b>	-	1.00	-
Diabetes duration	<=5.0 years	<b>1.31</b>	<b>1.20–1.43</b>	<b>1.33</b>	<b>1.20–1.48</b>
	5.1–10.0 years	<b>1.26</b>	<b>1.15–1.38</b>	<b>1.13</b>	<b>1.01–1.26</b>
	>10.0 years	1.00	-	1.00	-
Treatment class	OHAs + insulin	<b>1.31</b>	<b>1.20–1.43</b>	<b>1.33</b>	<b>1.20–1.48</b>
	Insulin only	<b>1.26</b>	<b>1.15–1.38</b>	<b>1.13</b>	<b>1.01–1.26</b>
	OHAs only	<b>1.00</b>	-	<b>1.00</b>	-
No. of diabetes complications	> = 1	0.94	0.87–1.01	0.94	0.86–1.03
	0	1.00	-	1.00	-
SF12 – PCS	Tertile 1	1.04	0.95–1.14	0.98	0.88–1.09
	Tertile 2	1.01	0.93–1.10	0.93	0.84–1.02
	Tertile 3	1.00	-	1.00	-
WHO-5	<=28	1.03	0.92–1.16	1.01	0.92–1.12
	>28	1.00	-	1.00	-
DES	Tertile 1	1.09	0.99–1.19	1.07	0.96–1.20
	Tertile 2	1.00	0.92–1.08	0.91	0.82–1.00
	Tertile 3	1.00	-	1.00	-
PAID-5 > 40	Yes	1.00	0.93–1.08	<b>1.15</b>	<b>1.05–1.25</b>
	No	1.00	-	<b>1.00</b>	-
GSDT	Tertile 1	1.24	0.93–1.65	0.91	0.62–1.33
	Tertile 2	1.09	0.99–1.19	1.07	0.96–1.20
	Tertile 3	1.00	0.92–1.08	0.91	0.82–1.00
PACIC	Tertile 1	1.02	0.93–1.11	0.87	0.77–1.00
	Tertile 2	0.94	0.87–1.03	0.92	0.82–1.02
	Tertile 3	1.00	-	1.00	-
HCCQ	Tertile 1	0.93	0.87–1.00	1.08	0.98–1.18
	Tertile 2–3	1.00	-	1.00	-



**Table 4** Factors associated with increased likelihood of poor metabolic control (HbA1c >=8.0%) (Continued)

PSS	Tertile 1	1.02	0.93–1.11	1.02	0.91–1.13
	Tertile 2	0.99	0.92–1.07	1.00	0.90–1.12
	Tertile 3	1.00	-	1.00	-

<sup>a</sup> Covariates tested in the fully adjusted model: Age, school education, living status, smoking, BMI, diabetes duration, glucose-lowering treatment class, presence of diabetes complications, PAID-5 > 40, WHO-5 <=28, and tertiles of SF12 – PCS, DES, GSDT, PACIC, HCCQ, and PSS. Tertiles were identified separately for men and women. Tertiles 2 and 3 coincided for HCCQ scores in both genders due to the extreme skewness of the distribution. Covariates related to statistically significant associations in men or women are in bold

symptom severity is associated with poorer diet and medication regimen adherence [30]. Also, women more often experience diabetes related distress than men [47]. Recently, Fisher [35] clarified that diabetes distress is not a proxy for clinical depression but reflects an emotional response to a demanding health-related condition; conversely, major depressive disorder is a psychiatric disorder which is not content-related in so far that it does not describe pathology based on relevant causes, perturbations or contextual stressors. The investigation of diabetes related and unrelated stressors should represent an integral component of ongoing comprehensive care for all patients with diabetes [35].

Additional elements deriving from previous qualitative and quantitative studies are that: Women with diabetes showed less patient satisfaction and a lower health-related quality of life than men with diabetes [48]; men are more concerned about how diabetes affects their provider role [49], whereas women worry more about how self-care will hinder their familial responsibilities [50]; women tend to sacrifice their dietary regimen for their family's food preferences [51]; men focused on practical aspects of SMBG whereas women focused on affective components of SMBG [44]; men find support from family and friends more helpful than do women [44]. Disease management programs for people with diabetes have been shown to save money and improve outcomes and it is recognized that they cannot ignore information about gender-specific differences [52].

In line with the cross-national design of the Diabetes Attitudes, Wishes and Needs second study (DAWN2™), BENCH-D study promotes benchmarking using psychometrically validated indicators to identify areas for improvement and best practices to drive changes that improve outcomes for people with diabetes [8]. Gender-differences in person-centered indicators identified in this analysis highlight the importance of considering gender as an important part of further research into person-centered diabetes care.

The study has strengths and limitations. As main strength, BENCH-D is the first study allowing a comprehensive evaluation of the association between clinical and person-centered care dimensions in the two genders, increasing the knowledge about the complex interplay among patient characteristics and perceptions.

Main limitations of this analysis is its cross-sectional nature, that does not allow to establish a cause-effect relationship between clinical and person-centered indicators. However, the longitudinal phase of the BENCH-D study, focusing on informing quality of care improvements through person-centered outcomes, will allow for an assessment of the person-centered mediators of impacts of educational approaches in diabetes care on clinical and quality of life outcomes.

Finally, the study sample is representative of patients attending diabetes clinics, and results cannot be generalized to individuals who only attend their general practitioner.

## Conclusions

In the BENCH-D study we collected reliable information about a range of person-centered outcomes such as depression, diabetes-related distress, self-care activities, empowerment, satisfaction with treatment, barriers to medication taking, satisfaction with access to chronic care and healthcare communication, and perceived social support in routine clinical practice and were able to identify important gender differences in the impact of diabetes. Specifically, we found that in T2DM women show poorer clinical and person-centered outcomes indicators than men. Diabetes-related distress plays a role as a correlate of metabolic control in women but not in men. The study provides new information about the interplay between clinical and person-centered indicators in men and women which may guide further improvements in diabetes education and support programs.

## Acknowledgements

We acknowledge all participating centers and Novo Nordisk SpA, Italy for the unconditional support to the study.

## Funding

The study was supported by an unconditional grant from Novo Nordisk S.p.A., Rome, Italy.

## Availability of data and material

The data that support the findings of this study are available from Associazione Medici Diabetologi (AMD) scientific society but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of AMD.

**Authors' contributions**

MCR, AN, and SES wrote the manuscript, MCR and GL analyzed data, all the authors contributed to discussion and revision of the manuscript. All authors approved the manuscript.

**Competing interests**

AN is a member of the advisory board of Novo Nordisk, Novartis, Merck Sharp & Dohme. He has received speaker fees from Novo Nordisk, Novartis, Merck Sharp & Dohme; AB is an employee of Novo Nordisk, Rome, Italy; SES is an employee of Novo Nordisk A/S, Copenhagen, Denmark. MCR, GL, BP, SG, MS, GV declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

The study protocol was approved by Ethics committees of all the participating centers; all enrolled patients signed an informed consent.

**the BENCH-D Study Group**

**Scientific committee:** A Nicolucci, G Vespasiani, MC Rossi, S Gentile, A Bulotta, SE Skovlund.

**Participating centers (by region):** LAZIO: E Forte, F Tuccinardi, A Griffo, Fondi (LT); S Leotta, L Fontana, M Altomare, L Pellegrini, Roma; F Malci, C Moscatelli, Subiaco (RM); P Tatti, M Neri, Marino (RM); G Santantonio, Civitavecchia (RM); F Chiaramonte, Roma; MARCHE: RA Rabini, S Rosati, F D'Angelo, Ancona; G Maolo, B Polenta, S Lardelli, AM Tesi, Macerata; L Cotti, G Garrapa, R Viola, M Manuela, F Lizzadro, Fano (PU); MG Cartechini, N Busciantella Ricci, G Agostinelli, Camerino (MC); G Vespasiani, I Meloncelli, M Galetta, V Marconi, L Carini, I Crema, L Clementi, San Benedetto del Tronto (AP); S Manfrini, L Olivi, Senigallia (AN); P Fogliani, R Maricotti, P Pantanetti, Fermo; A Spalluto, Pesaro; M Andreani, G Martinelli, Urbino (PU); PIEMONTE: A Chiambretti, R Fornengo, L Di Vito, M Albertone, V Magliano, D Cortale, Chivasso (TO); AR Bogazzi, M Rivelli, SB Del Rosso, F Picataggi, P Bonfani, E Baccaro, Venaria Reale (TO); M Comoglio, R Manti, O Boscolo, C Laiolo, Moncalieri (TO); A Clerico, L Richiardi, K Sinato, Torino; GP Carlesi, S Garrone, Novi Ligure (AL); G Magro, C Paverin, D Gaviglio, Cuneo; G Saglietti, Omegna (VB); L Monge, Torino; G Grassi, Torino; SICILIA: A Di Benedetto, M Russo, B Pintaudi, G Di Vieste, Messina; A Garofalo, F Vitale, L Bernardo, Vittoria (RG); G Saitta, Messina; A Lo Presti, Marsala (TP); MA Fulantelli, Palermo; G Mattina, M Cortese, A Parrinello, Palermo; V Provenzano, L Ferrara, R Ferranti, Partinico (PA); D Gioia, M Conti, Palermo.

**Coordinating center:** A Nicolucci, MC Rossi, G Lucisano, R Memmo - CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy

**Data managers and AMD regional coordinators:** L Fontana, F Chiaramonte (Lazio); R Viola, L Cotti (Marche); R Chiodo, L Monge (Piemonte); B Pintaudi, C De Francesco (Sicilia).

**Author details**

<sup>1</sup>CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. <sup>2</sup>S.S.D. Diabetologia, Niguarda Ca' Granda Hospital, Milan, Italy. <sup>3</sup>Novo Nordisk SpA, Rome, Italy. <sup>4</sup>Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy. <sup>5</sup>Novo Nordisk A/S, Soeborg, Denmark. <sup>6</sup>Diabetes Unit, Madonna del Soccorso Hospital, San Benedetto del Tronto, AP, Italy.

Received: 14 July 2016 Accepted: 7 February 2017

Published online: 21 February 2017

**References**

1. TRIAD Study Group. The translating research into action for diabetes (TRIAD) study: a multicenter study of diabetes in managed care. *Diabetes Care*. 2002;25:386–9.
2. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. *Ann Intern Med*. 2006;144:465–74.
3. Rossi MC, Nicolucci A, Arcangeli A, Associazione Medici Diabetologi Annals Study Group, et al. Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics. *Diabetes Care*. 2008;31:2166–8.
4. Rossi MC, Candido R, Ceriello A, et al. Trends over 8 years in quality of diabetes care: results of the AMD-annals continuous quality improvement initiative. *Acta Diabetol*. 2015;52:557–71.
5. Giorda CB, Nicolucci A, Pellegrini F, et al. Improving quality of care in people with type 2 diabetes through the associazione medici diabetologi-annals initiative: a long-term cost-effectiveness analysis. *Diabet Med*. 2014;31:615–23.
6. Rossi MC, Cristofaro MR, Gentile S, AMD-Annals Study Group, et al. Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the AMD-annals initiative. *Diabetes Care*. 2013;36:3162–68.
7. Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. *Diabetes Care*. 2008;31:1046–50.
8. Nicolucci A, Kovacs Burns K, DAWN2 Study Group, et al. Diabetes attitudes, wishes and needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. *Diabet Med*. 2013;30:767–77.
9. Nicolucci A, Kovacs Burns K, Holt RI, Lucisano G, Skovlund SE, Kokoszka A, Massi Benedetti M, Peyrot M. Correlates of psychological outcomes in people with diabetes: results from the second Diabetes Attitudes, Wishes and Needs (DAWN2™) study. *Diabet Med* 2016;33:1194–203.
10. Hajos TR, Pouwer F, Skovlund SE, Den Oudsten BL, Geelhoed-Duijvestijn PH, Tack C, Snoek FJ. Psychometric and screening properties of the WHO-5 well-being index in adult outpatients with type 1 or type 2 diabetes mellitus. *Diabet Med*. 2013;30:e63–69.
11. Nicolucci A, Rossi MC, Pellegrini F, et al. Benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) study: protocol, tools, and population. *Springerplus*. 2014;3:83.
12. Pintaudi B, Lucisano G, Gentile S, BENCH-D Study Group, et al. Correlates of diabetes-related distress in type 2 diabetes: findings from the benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) study. *J Psychosom Res*. 2015;79:348–54.
13. Rossi MC, Lucisano G, Funnell M, BENCH-D Study Group, et al. Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. *Patient Educ Couns*. 2015;98:1142–9.
14. Gondek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Lepelge A, Prieto L, Sullivan M. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. *International quality of life assessment*. *J Clin Epidemiol*. 1998;51:1171–8.
15. Bech P, Gudex C, Johansen KS. The WHO (ten) well-being index: validation in diabetes. *Psychother Psychosom*. 1996;65:183–90.
16. Snoek FJ, Pouwer F, Welch GW, Polonsky WH. Diabetes-related emotional distress in Dutch and U.S. diabetic patients: cross-cultural validity of the problem areas in diabetes scale. *Diabetes Care*. 2000;23:1305–9.
17. Pouwer F, Skinner TC, Pibernik-Okanovic M, et al. Serious diabetes-specific emotional problems and depression in a Croatian-Dutch-English Survey from the European depression in diabetes (EDID) research consortium. *Diabetes Res Clin Pract*. 2005;70:166–73.
18. McGuire BE, Morrison TG, Hermanns N, Skovlund S, Eldrup E, Gagliardino J, Kokoszka A, Matthews D, Pibernik-Okanovic M, Rodriguez-Saldaña J, de Wit M, Snoek FJ. Short-form measures of diabetes-related emotional distress: the problem areas in diabetes scale (PAID)-5 and PAID-1. *Diabetologia*. 2010;53:66.
19. Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, Schwartz CE. Assessment of diabetes-related distress. *Diabetes Care*. 1995;18:754.
20. Welch G, Weinger K, Anderson B, Polonsky WH. Responsiveness of the problem areas in diabetes (PAID) questionnaire. *Diabet Med*. 2003;20:69.
21. Williams GC, McGregor HA, Zeldman A, Freedman ZR, Deci EL. Testing a self-determination theory process model for promoting glycaemic control through diabetes self-management. *Health Psychol*. 2004;23:58.
22. Schafer LC, McCaul KD, Glasgow RE. Supportive and nonsupportive family behaviors: relationships to adherence and metabolic control in persons with type I diabetes. *Diabetes Care*. 1986;9:179.
23. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the patient assessment of chronic illness care (PACIC). *Med Care*. 2005;43:436.
24. Gugiu PC, Coryn C, Clark R, Kuehn A. Development and evaluation of the short version of the patient assessment of chronic illness care instrument. *Chron Illness*. 2009;5:268.

25. Anderson RM, Funnell MM, Fitzgerald JT, Marrero DG. The diabetes empowerment scale: a measure of psychosocial self-efficacy. *Diabetes Care*. 2000;23:739.
26. Anderson RM, Fitzgerald JT, Gruppen LD, Funnell MM, Oh MS. The diabetes empowerment scale-short form (DES-SF). *Diabetes Care*. 2003;26:1641.
27. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. *Diabetes Care*. 2000;23:943.
28. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. *Qual Life Res*. 2006;15:481.
29. Conference Report. 2nd International DAWN Summit: a call-to-action to improve psychosocial care for people with diabetes. *Pract Diab Int*. 2004;21:201.
30. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L, International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers. Results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. *Diabet Med*. 2005;22:1379.
31. Peyrot M, Burns KK, Davies M, Forbes A, Hermanns N, Holt R, Kalra S, Nicolucci A, Pouwer F, Wens J, Willaing I, Skovlund SE. Diabetes attitudes wishes and needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. *Diabetes Res Clin Pract*. 2013;99:174.
32. Wroe J. The 3rd International DAWN Summit: from research and practice to large-scale implementation. *Pract Diab Int*. 2006;23:313.
33. Franciosi M, Lucisano G, Pellegrini F, ROSES Study Group, et al. ROSES: role of self-monitoring of blood glucose and intensive education in patients with type 2 diabetes not receiving insulin. A pilot randomized clinical trial. *Diabet Med*. 2011;28:789–96.
34. Anderson RM, Funnell MM, Aikens JE, et al. Evaluating the efficacy of an empowerment-based self-management consultant intervention: results of a two-year randomized controlled trial. *Ther Patient Educ*. 2009;1:3–11.
35. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabet Med*. 2014;31:764–72.
36. Anderson RM, Funnell MM. Compliance and adherence are dysfunctional concepts in diabetes care. *Diabetes Educ*. 2000;26:597–604.
37. Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V. Gender medicine: a task for the third millennium. *Clin Chem Lab Med*. 2013;51:713–27.
38. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *Br Med J*. 2006;332:73–6.
39. Kalyani RR, Lazo M, Ouyang P, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. *Diabetes Care*. 2014;37:830–8.
40. Ballotari P, Ranieri SC, Luberto F, et al. Sex differences in cardiovascular mortality in diabetics and nondiabetic subjects: a population-based study (Italy). *Int J Endocrinol*. 2015;2015:914057.
41. Kautzky-Willer A, Kamyar MR, Gerhat D, et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. *Gend Med*. 2010;7:571–83.
42. Penno G, Solini A, Bonora E, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicenter study. *J Intern Med*. 2013;2:176–91.
43. Russo G, Pintauro B, Giorda C, et al. Age- and gender-related differences in LDL-cholesterol management in outpatients with type 2 diabetes mellitus. *Int J Endocrinol*. 2015;2015:957105.
44. Mathew R, Gucciardi E, De Melo M, Barata P. Self-management experiences among men and women with type 2 diabetes mellitus: a qualitative analysis. *BMC Fam Pract*. 2012;19:12.
45. Gucciardi E, Wang SC, DeMelo M, Amaral L, Stewart DE. Characteristics of men and women with diabetes: observations during Patients' initial visit to a diabetes education centre. *Can Fam Physician*. 2008;54:219–27.
46. Snoek FJ, Kersch NY, Eldrup E, et al. Monitoring of individual needs in diabetes (MIND)-2: follow-up data from the cross-national diabetes attitudes, wishes, and needs (DAWN) MIND study. *Diabetes Care*. 2012;35:2128–32.
47. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. *Arch Intern Med*. 2000;60:3278–85.
48. Graue M, Haugstvedt A, Wentzel-Larsen T, Iversen MM, Karlsen B, Rokne B. Diabetes-related emotional distress in adults: reliability and validity of the Norwegian versions of the problem areas in diabetes scale (PAID) and the diabetes distress scale (DDS). *Int J Nurs Stud*. 2012;49:174–82.
49. Jonsson PM, Sterky G, Gåfväls C, Ostman J. Gender equity in health care: the case of Swedish diabetes care. *Health Care Women Int*. 2000;21:413–31.
50. Hjelm KG, Bard K, Nyberg P, Apelqvist J. Beliefs about health and diabetes in men of difference ethnic origin. *J Adv Nurs*. 2005;50:47–59.
51. Sarkadi A, Rosenqvist U. Social network and role demands in women's type 2 diabetes: a model. *Health Care Women Int*. 2002;23:600–11.
52. Legato MJ, Gelzer A, Golland R, Writing Group for The Partnership for Gender-Specific Medicine, et al. Gender-specific care of the patient with diabetes: review and recommendations. *Gend Med*. 2006;3:131–58.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

